Introduction
============

Any degree of atrioventricular block (AVB) is a common complication of acute myocardial infarction (AMI).[@b1-cia-11-287]--[@b5-cia-11-287] High-degree atrioventricular block (HAVB) is seen in \~2% to 13% of all AMI cases.[@b6-cia-11-287]--[@b8-cia-11-287] Especially, in patients with ST-elevation myocardial infarction (STEMI), the occurrence of HAVB has been reported to be even higher than that in non-STEMI patients.[@b9-cia-11-287]--[@b11-cia-11-287] In particular, patients suffering from inferior STEMI tend to present with cardiogenic shock and bradyarrhythmia. In the thrombolytic era, HAVB in acute inferior myocardial infarction (MI) has been associated with older age, larger infarct size, female predominance, and higher mortality.[@b12-cia-11-287]--[@b15-cia-11-287] The mortality rate has been significantly improved as primary percutaneous coronary intervention (PCI) has replaced thrombolysis in the treatment of STEMI. However, in previous reports, the presence of HAVB was a significant prognostic factor for survival.[@b16-cia-11-287],[@b17-cia-11-287] Although there is a definite recommendation for treatment with primary PCI in these patients, no accepted guidelines exist for managing HAVB; however, patients were frequently treated with temporary right ventricular (RV) pacing (TP) in this clinical setting, at the clinician's discretion.[@b18-cia-11-287] The clinical significance of HAVB in a highly select group of patients suffering from inferior wall STEMI has not yet been studied. In addition, a study by Ho et al[@b19-cia-11-287] indicated that TP failed to improve mortality in anterior MI, but no other studies examined inferior wall STEMI. Therefore, the objective of this study was to investigate the incidence, predictors, and prognostic significance of HAVB in inferior STEMI. Furthermore, we investigated whether performing TP in patients with HAVB-complicated inferior wall STEMI improved the clinical outcome.

Methods
=======

Patients
--------

Among 295 patients who were diagnosed with STEMI involving the inferior wall from January 2009 to December 2014, we reviewed 72 patients with HAVB. Inferior wall STEMI was defined as typical chest pain or dyspnea lasting for \>30 minutes, ST-segment elevation ≥1.0 mm in more than two of the three inferior leads (II, III, and aVF), and elevated serum creatinine phosphokinase or troponin-T levels more than twice the upper limits of normal. HAVB was defined as a high-degree AVB, greater than a Mobitz type 2 AVB, including a complete AVB. A temporary RV pacemaker was implanted if there was hemodynamic instability and bradycardia with a heart rate of \<40 bpm refractory to intravenous administration of atropine or saline. Cardiogenic shock was defined as systolic blood pressure \<80 mmHg in spite of adequate fluid administration with or without bradycardia. All patients received successful primary PCI. TP was done via femoral vein approach, and RV lead was placed at the RV apex and the pacing rate was set at 50--80 bpm, at the physician's discretion. The clinical characteristics, laboratory data, angiographic findings, PCI procedural data, and inhospital and long-term clinical outcomes were compared between patients receiving TP and patients not receiving TP. MACEs (major adverse cardiocerebrovascular events) were defined as any cardiocerebrovascular events, such as any death from cardiocerebrovascular events, MI, and target vessel revascularization. Echocardiographic measurements of left ventricular ejection fraction were performed 1 day or 2 days after PCI. The study protocol was approved by the Institutional Review Board of St Vincent's Hospital (Suwon, South Korea; IRB No VC15RASI0034). All patients were retrospectively enrolled. However, informed written consent for the procedure was obtained from the patients.

Statistical analysis
--------------------

Analyses were performed using R 3.1.1 statistical software (R Development Core Team, 2014). Categorical variables were described using frequencies, while continuous variables were reported as median and interquartile ranges. Fisher's exact test or Pearson's *χ*^2^-test with Yates' continuity correction was used to compare categorical variables between patients with HAVB and those without HAVB and patients receiving TP and those not receiving TP. A two-sided *t*-test was used to compare continuous variables. The survival of patients with and without HAVB was determined using the Kaplan--Meier method and compared using a log-rank test.

Results
=======

The baseline characteristics of 72 patients are summarized in [Table 1](#t1-cia-11-287){ref-type="table"}. Among 72 HAVB patients, 16 (22.2%) were implanted with a temporary pacemaker. There were no significant differences in sex, age, basal metabolic index, lipid profiles, peak cardiac markers, inflammatory status, or prevalence of underlying medical conditions between TP and non-TP groups. However, there were statistical differences in serum creatinine level and smoking status. Never smoker and ex-smoker with HAVB tended to be more prevalent in the TP group (39.3% vs 75%, *P*=0.041). Clinical presentation at emergency room and periprocedural data are summarized in [Tables 2](#t2-cia-11-287){ref-type="table"} and [3](#t3-cia-11-287){ref-type="table"}, respectively. Basal rhythm, heart rate, bundle branch block, and left ventricular systolic function at emergency room at presentation were not different between the two groups. However, among the 25 patients presented with cardiogenic shock, 12 patients underwent TP, which seemed to be a major factor to decide TP (*P*\<0.001). In our study population, most of the HAVBs were caused by right coronary artery infarction (97.2%). Door-to-balloon time and needle-to-balloon time were similar between the two groups. However, more patients with TP underwent primary PCI via femoral access (25% vs 75%, *P*=0.001), had intra-aortic balloon pump support (1.8% vs 18.8%, *P*=0.046), and had longer radiation exposure time (10 minutes vs 14.7 minutes, *P*=0.044) than those in the non-TP group. TP group patients also stayed longer in the hospital than the non-TP group (5 days vs 6 days, *P*=0.03). HAVB was reversed in all patients after primary PCI, and in TP, pacing lead was removed mostly in the cardiac catheterization laboratory soon after reperfusion.

After a median of 344 (range, 105.5--641) days of follow-up, the mortality rate (*P*=0.89) and MACEs (*P*=0.53) were not significantly different between the two groups. Especially, there was no short-term (\<90 days) mortality event in both groups. During the long-term follow-up period, five MACEs occurred in four patients: four MACEs in the non-TP group (three patients had cerebrovascular accident and one patient died) and one MACE in the TP group ([Table 4](#t4-cia-11-287){ref-type="table"}). Finally, Kaplan--Meier analysis showed a comparable prognosis based on the mortality events between patients with and without TP in acute inferior wall STEMI (*P*=0.53; [Figure 1](#f1-cia-11-287){ref-type="fig"}).

Discussion
==========

HAVB is a common complication of AMI. In particular, patients with inferior AMI are more prone to developing HAVB compared with patients with anterior AMI.[@b16-cia-11-287] By extension, STEMI increases the risk of HAVB compared with patients with non-STEMI. The mechanism of HAVB in inferior wall STEMI is not fully elucidated. However, as mentioned in our previous study,[@b20-cia-11-287] we consider that the underlying major cause of bradyarrhythmia results from the cardioinhibitory (Bezold--Jarisch) reflexes arising from vagal efferent nerves in the ischemic ventricular wall. In this study, we investigated the prognostic significance of TP in 72 patients with inferior STEMI treated with primary PCI. There are some studies demonstrating poor clinical outcomes in HAVB, such as in cases of cardiogenic shock, atrioventricular arrhythmias, and short-term (\<30 days) mortality rate.[@b3-cia-11-287],[@b15-cia-11-287],[@b17-cia-11-287],[@b21-cia-11-287] In our study patients with a manifested cardiogenic shock, more TP was performed; in addition, femoral access was more frequent in the TP group, which was estimated as interrelated. However, in our study, all the patients, even those with HAVB, recovered from complete AVB with low short- and long-term mortality rate. The result is contrary to previous reports that HAVB-complicated inferior STEMI was associated with poor cardiovascular outcomes.[@b3-cia-11-287],[@b4-cia-11-287],[@b11-cia-11-287],[@b14-cia-11-287],[@b22-cia-11-287],[@b23-cia-11-287]

Our study has several limitations. First, it was conducted with a relatively small number of patients, resulting in an insufficient power to postulate generalizations. However, this study was designed to determine the effect of TP in patients with HAVB-complicated inferior wall STEMI on a relatively large scale at a local center. Even though the numbers were small, the study group was reduced to a particular group of inferior STEMI that underwent successful primary PCI. Second, the follow-up period was too short to generalize any long-term outcomes, although it contained a wide variation in the follow-up duration (0--1,071 days). Third, to evaluate the effect of TP, we should have distributed patients evenly in the TP and non-TP groups. However, the decision to select the distribution of the patients was at the clinician's discretion, and there were also related ethical issues to consider for patient distribution in the study.

However, our study also has several strengths. First, it was conducted using a discrete population of inferior STEMI patients from one center during a 6-year period with consistent criteria for HAVB. Although primary PCI is usually recommended for all STEMI patients in present-day practice, there have been no other studies conducted specifically on inferior STEMI with HAVB to define the prognostic implication of TP in such a clinical setting. Moreover, in our study, all patients received primary PCI. After primary PCI, HAVB was reversed in all patients, indicating that TP is unnecessary in inferior STEMI treated successfully with primary PCI. In our hospital, a temporary pacemaker was implanted if there was hemodynamic instability and bradycardia with a heart rate ≤40 bpm refractory to intravenous atropine administration with fluids. With experience, we recently performed primary PCI without TP in STEMI patients with HAVB. Most of the patients were stable and HAVB could be reversed with primary PCI.

Conclusion
==========

Primary PCI solely can ameliorate HAVB-complicated inferior STEMI without using a time-consuming and cumbersome TP procedure. Thus, we recommend primary reperfusion therapy with PCI as the first-line therapy in most patients with HAVB-complicated acute inferior MI, because early reperfusion therapy solely reverses HAVB without the need of TP. However, we should consider applying all the possible measures to maintain the hemodynamic stability of patients, if symptomatic or hemodynamic unstable bradycardia persists even after successful reperfusion.

Although our study has several limitations, these results may help in decision-making for clinicians and further contribute some part in future guidelines dealing with patients suffering from HAVB-complicated inferior STEMI.
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###### 

Baseline characteristics comparing patients with/without TP

                              No TP (N=56)                 TP (N=16)                    *P*-value
  --------------------------- ---------------------------- ---------------------------- -------------------------------------------------
  Age (years)                 62 (56--68)                  70 (60--75)                  0.13
  Sex                                                                                   
   Male                       39 (69.6%)                   11 (68.8%)                   
   Female                     17 (30.4%)                   5 (31.2%)                    
  Diabetes                    11 (19.6%)                   4 (25%)                      0.91
  Hypertension                28 (50%)                     9 (56.2%)                    0.88
  Coronary artery disease     3 (5.4%)                     1 (6.2%)                     1.00
  Stroke                      4 (7.1%)                     2 (12.5%)                    0.86
  CKD (GFR \#60 mL/min)       3 (5.4%)                     0 (0%)                       0.81
  Smoking                                                                               0.04[\*](#tfn1-cia-11-287){ref-type="table-fn"}
   Never                      17 (30.4%)                   9 (56.2%)                    
   Ex-smoker                  5 (8.9%)                     3 (18.8%)                    
   Current smoker             34 (60.7%)                   4 (25%)                      
  Height (cm)                 165.0 (160.0--170.0)         168.0 (159.0--172.5)         0.66
  Weight (kg)                 63.0 (58--70)                67.0 (53.5--72.0)            0.52
  Creatinine (mg/dL)          1.0 (0.9--1.2)               1.1 (1.0--1.5)               0.04[\*](#tfn1-cia-11-287){ref-type="table-fn"}
  Peak CPK (IU/L)             1,712.0 (1,032.0--2,763.5)   2,347.5 (1,127.0--3,375.0)   0.53
  CK-MB (ng/mL)               141.3 (87.1--280.8)          234.5 (54.4--300.0)          0.86
  Total cholesterol (mg/dL)   167.5 (143.0--203.5)         163.0 (144.0--185.5)         0.76
  LDL (mg/dL)                 116.0 (88.5--141.5)          110.0 (96.0--153.5)          0.76
  HDL (mg/dL)                 34.0 (30.0--42.0)            37.5 (29.5--50.0)            0.47
  Triglyceride (mg/dL)        91.0 (54.5--135.0)           80.0 (43.0--107.5)           0.91

**Notes:**

Denotes *P*-value \<0.05 of significance. Data presented as mean (1st quartile-3rd quartile) unless otherwise stated.

**Abbreviations:** TP, temporary pacing; CKD, chronic kidney disease; GFR, glomerular filtration rate; CPK, creatinine phosphokinase; LDL, low-density lipoprotein; HDL, high-density lipoprotein; CK-MB, creatine kinase-MB.

###### 

Comparison of ECG parameters and presentation status at emergency room with/without TP

                           No TP (N=56)        TP (N=16)           *P*-value
  ------------------------ ------------------- ------------------- ----------------------------------------------------
  Rhythm                                                           0.99
   Sinus rhythm            40 (72.7%)          11 (73.3%)          
   Escape rhythm           7 (12.7%)           2 (13.3%)           
   Atrial fibrillation     8 (14.5%)           2 (13.3%)           
  Heart rate (bpm)                                                 0.12
   \<40                    16 (28.6%)          9 (56.2%)           
   40--60                  29 (51.8%)          5 (31.2%)           
   \>60                    11 (19.6%)          2 (12.5%)           
  BBB                                                              0.61
   No                      50 (89.3%)          14 (87.5%)          
   RBBB                    4 (7.1%)            2 (12.5%)           
   LBBB                    2 (3.6%)            0 (0%)              
  LVEF (%)                 57.4 (52.6--62.0)   59.0 (54.4--64.3)   0.42
  Ventricular arrhythmia   5 (8.9%)            3 (18.8%)           0.52
  DC cardioversion         4 (7.1%)            2 (12.5%)           0.86
  Shock                    13 (23.2%)          12 (75%)            \<0.001[\*](#tfn3-cia-11-287){ref-type="table-fn"}
  CPR                      4 (7.1%)            1 (6.2%)            1

**Notes:**

Denotes *P*-value \<0.05 of significance. Data presented as range unless otherwise noted.

**Abbreviations:** ECG, electrocardiogram; TP, temporary pacing; BBB, bundle branch block; RBBB, right bundle branch block; LBBB, left bundle branch block; LVEF, left ventricular ejection fraction; DC, direct current; CPR, cardiopulmonary resuscitation.

###### 

Periprocedural characteristics comparing patients with/without TP

                                 No TP (N=56)           TP (N=16)              *P*-value
  ------------------------------ ---------------------- ---------------------- --------------------------------------------------
  Culprit lesion                                                               0.96
   Proximal RCA                  24 (42.9%)             8 (50.0%)              
   Mid RCA                       23 (41.1%)             6 (37.5%)              
   Distal RCA                    5 (8.9%)               2 (12.5%)              
   Right posterolateral branch   2 (3.6%)               0 (0%)                 
   Mid LCX                       1 (1.8%)               0 (0%)                 
   Obtuse marginal branch        1 (1.8%)               0 (0%)                 
  Needle-to-balloon time (min)   9.0 (5.0--15.0)        12.9 (8.1--12.0)       0.07
  Door-to-balloon time (min)     71.0 (58.0--81.0)      77.0 (63.0--103.0)     0.25
  Fluoroscopic time (min)        10.0 (6.3--17.3)       14.7 (10.3--19.4)      0.04[\*](#tfn5-cia-11-287){ref-type="table-fn"}
  Contrast volume (mL)           150.0 (100.0--200.0)   172.0 (115.0--200.0)   0.81
  Entry of vascular access                                                     0.001[\*](#tfn5-cia-11-287){ref-type="table-fn"}
   Femoral                       14 (25.0%)             12 (75.0%)             
   Radial                        42 (75.0%)             4 (25.0%)              
  No reflow phenomenon           2 (3.6%)               3 (18.8%)              0.12
  IABP support                   1 (1.8%)               3 (18.8%)              0.046[\*](#tfn5-cia-11-287){ref-type="table-fn"}
  Hospital day (days)            5.0 (4.0--7.0)         6.0 (6.0--12.0)        0.03[\*](#tfn5-cia-11-287){ref-type="table-fn"}

**Notes:**

Denotes *P*-value \<0.05 of significance. Data presented as range unless otherwise noted.

**Abbreviations:** TP, temporary pacing; RCA, right coronary artery; IABP, intra-aortic balloon pump; LCX, left circumflex artery.

###### 

Clinical outcomes during long-term follow-up \>90 days, comparing patients with/without TP

                                    No TP (N=56)           TP (N=16)              *P*-value
  --------------------------------- ---------------------- ---------------------- -----------
  Death                             1 (1.8%)               0 (0%)                 0.53
  Myocardial infarction             0 (0%)                 1 (6.2%)               0.50
  Target vessel revascularization   0 (0%)                 0 (0%)                 1.00
  Cerebrovascular accident          3 (5.4%)               0 (0%)                 0.89
  MACE                              4 (7.2%)               1 (6.2%)               0.53
  Follow-up duration (days)         373.5 (209.0--576.0)   431.5 (145.5--746.5)   0.48

**Note:** Data presented as range unless otherwise noted.

**Abbreviations:** TP, temporary pacing; MACE, major adverse cardiocerebrovascular event.
